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Sara Leah Abraham 
Introduction 
Cardiovascular disease is a generic term that refers to any illness or disorder that involves 
the heart and its vessels or the blood vessels of the body.  Cardiovascular disease has been 
accepted as the leading cause of death worldwide.   According to the Centers for Disease 
Control’s National Vital Statistics Reports, twenty six percent of deaths in 2006, 631,636  in 
total, were caused by diseases of the heart (Heron et al. 2009). 
One of the most common of all cardiovascular diseases is Ischaemic Heart Disease. This 
coronary artery disease often leads to Acute Myocardial Infarction, more commonly known as a 
heart attack.  An ischemia occurs when an organ is receiving an insufficient supply of blood, 
often caused by a clogged artery (De Milto 2006).  Atherosclerosis and blood clots in some of 
the larger coronary arteries are the most common condition to block coronary circulation.  
Coronary arteries take rise from the root of the aorta and spread out over the epicardium.  These 
arteries branch out into energy hungry cardiac muscle, the myocardium, to supply it with oxygen 
and nutrients.  The blockage of these deep arteries is known as myocardial ischemia.  When 
ischemia to a specific region is severe, injury occurs (American Heart Association 2008).  When 
blockage results in cell death, the condition is called an infarction.  
Myocardial infarction is characterized by necrosis, cellular death in an isolated region of 
the heart.  Cellular death stimulates the migration of macrophages to the infarct zone. They 
remove the necrotic tissue, and the area is refilled with a dense collagen scar, leading to a 
decrease in muscle thickness.  The scar tissue, by and large, is acellular, and does not have the 
biochemical properties of myocardial cells.  This can lead to electrical inconsistencies, loss of 
structural integrity, and mechanical dysfunction, such as arrhythmias.  Together, these 
abnormalities can lead to complete heart failure (Joggerst and Hatzopoulos 2009). 
Current treatments for post myocardial infarction patients aim to assist in the healing 
process and prevent further heart attacks, such as cholesterol-lowering medications and 
angiotensin inhibitors. A rehabilitation plan that includes blood pressure and cholesterol 
management may be set up. Diet and exercise regimes may change (Mayo Clinic 2010). 
Ultimately, though, once an area of the myocardium is dead, it’s irreversible. It is because of this 
that scientists are looking for ways to alleviate the effects of myocardial ischemia and infarction 
by means of cardiac regeneration. 
Cell Therapy 
The basic concept of cell therapy is that exogenous, or possibly even autologous cells 
implanted into diseased tissue can recover and improve its function by substituting for the 
resident cells that have died.  The improved neurologic function of Parkinson’s patients that 
underwent the grafting of intracerebral dopaminergic cells and the prospect of weaning a number 
of diabetics off insulin after Langerhan islet transplants provide a good indication that cell 
therapy can be clinically effective.  Transplanted cells must be engrafted in very specific 
quantities, and they must be able to integrate into normal host tissue without excess reproduction 
20	
	
and other adverse effects.  When attempts to ameliorate the effects of myocardial infarction by 
converting the infarct zone into contractile tissue with the use of viral vectors encoded with 
muscle specific master genes failed, cell therapy became an increasingly attractive method of 
attempted cardiac regeneration (Menasche 2004). 
Stem Cells: 
Stem cells can be defined by two significant characteristics.  First and foremost, they 
must be able to self-renew.  They must be able to go through many cycles of mitosis and still 
remain in their undifferentiated state.  Secondly, a stem cell must have the capability to 
differentiate into various specialized cell types.  The effectiveness and value of stem cells are 
often based on their potential to do this.  Pluripotent stem cells are able to differentiate into 
specialized mature cells from the three germ layers.  The embryonic stem cell is the classic 
example of a pluripotent stem cell.  Multipotent stem cells, alternatively, are limited to 
differentiating into mature cells of directly related lineages, generally from the same germ layer.  
Adult stem cells, sometimes called somatic stem cells, that are derived from postnatal, or even 
fully mature tissue are generally multipotent.  Some adult stem cells sometimes have a more 
limited capacity for self-renewal, and are committed to differentiation into specific lineages.  
These cells are called adult progenitor cells (Cook et al. 2009).  Until very recently, the 
myocardium has been labeled and viewed as an end-differentiated organ – one without any 
potential for regeneration.  Certain types of stem cells are currently being tested as sources for 
regenerative potential for the heart.  There is a new availability for hope in the possibility of 
reconstructing the infracted, failing ventricle (Loscalzo et al. 2008). 
Mesenchymal Stem Cells: 
Mesenchymal stem cells (MSCs) were first identified by their ability to form fibroblast 
like populations, and have been recognized for their plasticity.  In the past, they have been 
known to help normal bone regenerate in vivo.  They were initially discovered in the stroma of 
bone marrow.  It has been established that by secreting growth factors important for proliferation 
and colony stimulating factors, MSCs provide support for hematopoiesis.  While generally 
harvested from bone marrow, MSCs have recently been found in and isolated from the placenta, 
adipose tissue, the liver, and umbilical cord blood.  MSCs, an integral part of the composition of 
endothelium (perivascular cells), are now seen as ubiquitous.   No single, specific marker for 
MSCs has been discovered yet, though they are characteristically lacking typical hematopoietic 
antigens, such as CD 34, CD 44 an45, and more.  MSCs produce a large number of cytokines 
and growth factors, including the important vascular endothelial growth factor .  The hallmark 
and most distinctive feature of the mesenchymal stem cell is its inherent ability to differentiate 
into anything of mesodermal lineage, such as bone, cartilage, tendon, muscle, and adipose tissue.    
The main advantage of MSCs in cell therapy is their unique immunological properties.  They can 
be transplanted across major histocompatibility barriers; recipients will not need to take 
immunosuppressants.  They can be taken from any healthy donor, even an unrelated one, and 
cryopreserved until needed.  With their ability to self-renew and differentiate, MSCs can be 
induced to differentiate into cardiomyocytes, and there is evidence that MSCs migrate primarily 
to sites of inflammation. These factors together suggest their potential for treatment for ischemic 
myocardial infarction.  A disadvantage of MSCs is that they are perhaps too heterogenic, and 
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there are concerns that they may provide unexpected results, such as ossification (Cook et al. 
2009).   
Intracoronary injections of autologous bone marrow have led to moderate recovery of 
cardiac function, but clinical findings show that bone marrow cells don’t actually engraft in the 
infarct zone, nor do they reduce infarct size.  A placebo controlled study was therefore done to 
increase the evidence that MSCs have reparative properties.  To ensure that mesenchymal stem 
cell grafts were allogeneic, donor pigs were of a different strain than recipient pigs.  The bone 
marrow was obtained from the iliac crests of male swine.  MSCs were identified and isolated by 
density, and were plated to expand in culture, and were then cryopreserved.  They were 
magnetically stained in order to be later identified under MRI.  Recipient pigs underwent a 
surgically induced myocardial infarction via balloon occlusion of the left anterior descending 
coronary artery for sixty minutes, followed by reperfusion; left ventricular performance and 
cardiac oxygen consumption was measured.  After three days, animals were randomly chosen to 
receive intramyocardial infusions of allogeneic porcine MSCs or a placebo through a needle 
tipped injection catheter.   Contractility of the myocardium was measured by the maximal rate of 
isovolumetric contraction and ventricular elastance, and the ratio of left ventricular systolic 
pressure to stroke dimension.   At day three post injection, no animal had died or shown signs of 
arrhythmias, or shown signs of cardiac perforation, thus indicating that the method of delivery 
was safe.  The animals were euthanized after eight weeks.  Their hearts were analyzed in gross 
and microscopic levels.  Tissue samples were taken from the infarct zone, the infarct border, and 
remote tissue.  Immunostaining revealed the presence of α-actinin, troponin-T, and myosin heavy 
chains.  Histologic evaluation demonstrated that MSCs were found present throughout the infarct 
and border regions, and they expressed muscle specific proteins that weren’t found while they 
were still in culture plates.  They were also found in vascular structures, where they had 
incorporated into vascular smooth muscle and endothelium.  Myocardial infarction normally 
begins at the subendocardial area of the myocardium and moves out through the midmyocardium 




region.  In animals that received a mesenchymal stem cell transplant, the infarct region was 
confined to the midmyocardium.  When measured, the subendocardial rim was thicker in the 
mesenchymal stem cell-treated group than in control groups.   MSCs probably caused this 
cardiac regeneration of the subendocardium.  The effects of the transplant on cardiac function are 
as follows (see table 1).  
The animals exhibited recovery to almost normal levels of both systolic and diastolic function.  
Myocardial efficiency increased, almost bringing stroke work back to a normal level.   Cardiac 
energy metabolism was nearly recovered (Amado et al 2005).   
Hematopoietic Progenitor Cells /Bone Marrow Mononuclear Cells: 
Hematopoietic progenitor cells are the only stem or progenitor cell that are routine in 
clinical use today, due in part to the fact that they are easy to isolate and feasible to implant 
(Joggerst and Hatzopoulos 2009).  They reside in bone marrow, and are responsible for making 
all blood cells, constantly repopulating the hematopoietic and immune systems.  They are used in 
bone marrow transplants to treat many disorders, including leukemia and aplastic anemia.  In 
humans, hematopoietic progenitor cells are identified by the CD 34 marker (a surface 
gylocoprotein).  Hematopoietic progenitor cells home to bone marrow in healthy mammals, 
where they adhere firmly to the endothelium.  Whether or not hematopoietic progenitor cells 
actively participate in the repair of cardiomyocytes after an infarction is a matter of debate, 
though they have been known to differentiate into skeletal muscle fibers.    It is generally 
accepted, though, that hematopoietic progenitor cells are responsible for the inflammatory 
wound healing process (Cook et al. 2009). Experimental studies have suggested that 
intramyocardial or intravascular administration of bone marrow derived hematopoietic 
progenitor cells may play a part in the functional regeneration of infarcted cardiac muscle by 
enhancing neovasculogenesis of an ischemic myocardium (Schachinger et al. 2006).   
Patients, aged eighteen to eighty, were eligible for the REPAIR-AMI (Reinfusion of 
Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial if they’d 
had an ST-elevation myocardial infarction with residual left ventricular wall motion abnormality 
and a significantly decreased left ventricular ejection fraction (Schachinger et al. 2006).  (A 
normal resting ejection fraction, the fraction of blood pushed out of the heart by the ventricles 
per beat, is 62.3±6.1% [Pfisterer and Battler 1985].)  This placebo controlled, double blind 
randomized trial was performed in seventeen different centers, at a median of 4 days after AMI 
reperfusion therapy.   Bone marrow biopsies were done on 204 patients and the aspirate was sent 
to a single cell-processing laboratory, where patients were randomized to receive either an 
intravascular infusion of bone marrow derived hematopoietic progenitor cells (101 patients) or a 
placebo medium (103 patients).  This infusion was done using a stop-flow technique via balloon 
positioned in the infarct-related coronary artery.  After four months, the BMC (bone marrow 
cells, and alternate name for hematopoietic progenitor cells) group showed enhanced contractile 
recovery of left ventricular function.  One year later, the results of the experiment were 
measured.  A total of eight deaths occurred in the year, six in the placebo group and 2 in the 
BMC group.  None of the patients in the BMC group experienced a second myocardial 
infarction, while six patients in the placebo group suffered a total of eight myocardial infarctions, 
six of which were located to the target blood vessel.  While on paper these numbers may seem 
small, statistically, the difference is significant.  Similarly, additional revascularization 
procedures were needed less frequently in the BMC group than in the placebo group.  Thirty-
 
(Amado et al. 2005) 
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eight revascularizations were needed in thirty seven patients of the placebo group, while only 
twenty five were needed in twenty two patients of the BMC group (Schachinger et al. 2006).        
The BMC group can be seen as a predictor of a reduced cardiovascular event rate.  It is 
reassuring that in every endpoint, be it death, another myocardial infarction, or rehospitalization 
due to heart failure, there was a trend, albeit a statistically insignificant one, in favor of the BMC 
group.  This data suggests that the contractile recovery seen at four months may possibly 
translate into a better clinical outcome one year post BMC infusion (Schachinger et al. 2006). 
Cardiac Stem Cells:  
The steps that have been made towards cardiac regeneration through the various stem cell 
types prompted further research into any natural regenerative properties and mechanisms that 
cardiac tissue might have.  The heart has always been viewed as a postmitotic organ because 
mature cardiomyocytes don’t reproduce or propagate.  Contradictory facts seemed to accumulate 
as cardiomyocytes were discovered proliferating and reentering the cell cycle in certain 
pathological conditions such as ischemia and hypertension (Joggerst and Hatzopoulos 
2009).  After a female heart was transplanted into a man, male cardiomyocytes and endothelial 
cells were found growing within the heart.  Y-chromosome positive cells must have migrated 
from the recipient’s atrial stump or bone marrow into the donated heart, and differentiated into 
(Schachinger et al. 2006)	
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functional cardiomyocytes (Quaini et al. 2002).  Since then, several types of cells have been 
discovered in the adult heart that have stem cell characteristics.  One stem cell characteristic is a 
cytoplasmic exclusion of certain vital dyes, like Hoechst 33342 and Rhodamine 
123.  Populations of these cells, sometimes called side population cells, have been found in 
various organs, such as skeletal muscle, bone marrow, and adipose tissue.  These cells have 
recently been found in cardiac tissue as well, concentrated in the deep tissue of atria and 
apex.  Cardiac side population cells have been seen to differentiate into cardiomyocytes, 
suggesting that they may in fact be cardiac progenitor cells.  After cardiac injury, such as 
ischemia, these cardiac side population cells are mobilized and move to the injury site.  The 
apparent conflict between the existence of cardiac progenitor cells and the heart’s lack of 
regenerative ability is still puzzling to researchers, though two theories have been developed.  
The first is that these cells, along with mature cardiomyocytes, cannot survive the hypoxic 
conditions of ischemia.  The second is that the pool of cardiac stem cells diminishes with age, 
which can possibly contribute to lack of regeneration in the elderly (Joggerst and Hatzopoulos 
2009). 
Studies have found what have been loosely termed human cardiac stem cells in small 
niches in the heart.  These small clusters of human cardiac stem cells are closely connected to 
myocytes and fibroblasts by gap junctions and adherans junctions.  The myocytes and fibroblasts 
form supporting walls that contain the cardiac stem cells.  These cells are very obviously 
committed to myocyte lineage.  Stem cell antigen C-kitPOS, sarcomeric proteins, and myocyte 
transcription factors are co-expressed consistently, though they sometimes also expressed 
transcription factors for endothelial cells and smooth muscle cells.  Myocardial samples were 
enzymatically dissociated, and C-kitPOS cells sorted out and plated; multicellular clones were 
formed successfully in eight out of twelve cases.  These clones were, in turn, plated again, or 
placed in individual wells.  Doubling time was approximated at 29 hours.  These cells 
differentiated into cardiomyocytes, smooth muscle cells, and endothelial cells.  Developing 
myocytes had sarcomeric units, were striated, and showed contractile activity after electrical 
stimulation (Bearzi and Rota 2007).    
Human cardiac stem cells were collected from eight patients and injected into infarcted 
mouse or rat heart, forming chimeric organs that contained human myocytes and coronary 
vessels.  Cell therapy led to regeneration in the infarct zone.  The new cells tested positive for α-
sarcomeric actin and human DNA sequences were found in seventeen out of twenty five treated 
mice and fourteen out of nineteen rats.  Of the new tissue, ≈84% was myocardial and ≈8% 
consisted of new microvasculature, making an approximate ration of one capillary to eight 
cardiomyocytes. Two different lentiviruses were injected into the cardiac stem cells and the 
infarcted rat and mice hearts to promote different dye production, and the results showed that 
there had been no cell fusion.  The new cardiomyocytes were all human, and that animal 
cardiomyocytes did not contribute to the regeneration or repair.  An examination of ECG done 
on injected hearts showed that tissue regeneration had partially restored contractile function in 
the infarct, resulting in an increased ejection fraction and a general improvement of ventricular 
function.  When examined, the synchronicity of calcium tracings in both human and rat 
cardiomyocytes proved their functional integration.  An occasional protein was even found 
linking human and rodent cardiomyocytes.  Together, these observations all prove the role of 
transplanted human cardiac stem cells in cardiac homeostasis and myocardial regeneration 




While the regenerative ability of cardiac muscle cells is a relatively new development, it 
has been known for a while that skeletal myoblasts retain the potential to regenerate. This is due 
in large part to the presence of stem cells, sometimes called satellite cells, in this case, because of 
their location in the periphery of mature, multinucleated muscle tubules.  A billion or more 
myoblasts can be easily cultured in the laboratory from a single small piece of muscle tissue.  
Myoblast therapy was developed originally as a possible treatment for muscular dystrophy, 
because myoblasts from a normal donor would fuse with the muscle of the recipient to provide 
normal proteins absent from dystrophic patient.  In 1992, scientists realized the potential use of 
skeletal myoblasts in cardiac regeneration.   Over time, experiments proved that myoblast 
transplantation could repair a damaged myocardium when cells engraft and integrate, adding 
new contractile muscle to the heart, and by promoting cardiac repair, including rejuvenation of 
blood supply, and therefore oxygen and nutrients, to previously damaged areas (Dinsmore and 
Nabil 2006).   
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Of one the wonderful things about myoblast therapy is that it can be autologus.  In 
preparation for transplant, a skeletal muscle biopsy about five grams is done.  The muscle is 
trimmed of all connective tissue and minced.  It then goes through several cycles of digestion 
with trypsin and collagenase.  The resulting cells are plated and grown in a medium developed 
primarily for supporting myoblast growth.   The actual number of cells used for transplant can be 
anywhere from three hundred million to eight hundred million.   Animal studies done with 
transplantation of skeletal myoblasts into ischemically damaged myocardium have demonstrated 
good results.  They show that skeletal myoblasts engraft and contribute to improved heart 
function; they have survived long term without manifesting adverse affects, such as arrhythmias.  
Autologus rat myoblasts grafted into ischemic myocardium survived both inside and out  of the 
infarct zone, and fused, forming myotubes in close contact with myocytes at the border of the 
infarct zone.   Myocardial contractility and cardiac output increased in comparison to the control 
group.   Ventricular volume and remodeling were minimal.   In sheep, progressive heart failure 
halted short term , and was functionally reversed in the long term.  Skeletal muscle fibers formed 
organized bundles that co-aligned with adjoining cardiac muscle.   Muscle density in areas of 
ischemic collagen scars was almost restored to normal.   Clinical studies have been done in both 
the USA and Europe, and direct evidence for skeletal myoblast survival had been provided.  
Autologus myoblasts formed myofibers that survived in the human myocardium and aligned 
parallel to host cardiac muscle fibers, showing potential for synchronized contraction. This in 
turn, can contribute to improvements in systolic and diastolic functioning.   Left ventricular 
ejection fraction increased.  Tissue viability scanning of the scarred region of the myocardium 
six months post transplant showed improved metabolic activity (Dinsmore and Nabil 2006).  
While the theory shows great promise, a few problems with myoblast transplantation were 
exhibited in some trials.   Ten patients that received myoblast transplants reported severe left 
ventricular dysfunction.  Their ejection fraction dropped significantly to below 35%.  In the 
MAGIC (Myoblast Autologuous Grafting in Ischemic Cardiomyopathy) trial, four out of sixty 
four patients developed ventricular tachycardia after receiving skeletal myoblast injections in 
coronary artery bypass grafting, and twenty four more were expected to.  Therefore, clinicians 
Autologous human myoblast transplantation in a 
human patient as an adjunct to coronary artery 





must proceed with caution in regard to arrhythmias in pursuing myoblast therapy.  Furthermore, 
many myocardial infarction patients are not surgical candidates, and a less invasive method of 
delivery must be devised (Dinsmore and Nabil 2006). 
Of all the various studies done to investigate the effects of cell therapy on myocardial 
infarction, few have taken timing into account, and as of yet, the optimal time for cell 
transplantation in heart attack patients remains unclear.  One such study was done in 2009 using 
human umbilical cord blood cells (HUCBC), which are rich in mesenchymal progenitor cells and 
contain endothelial cell precursors with huge in vitro proliferation capabilities.   Myocardial 
infarction was identified in eighty male Wistar rats by elevated ST segments in a transthoracic 
ECG.  Equal volumes of either HUCBCs or a phosphate buffered saline placebo were injected 
into the rats through a caudal vein at days one, five, ten, and thirty after myocardial infarction.  
The rats were all sacrificed four weeks post infusion, after a hemodynamic assessment and an 
ECG.  Mortality in rats transfused on day one post infarction was 40%, most deaths occurring 
within one week.  Rats infused on day five and day ten both hard mortality rates of 10%, and 
those injected thirty days after the myocardial infarction had a mortality rate of 30%, usually at 
three weeks post infarction.    Before injection, all rats had a similar left ventricular ejection 
fraction of about 45%.  After four weeks, the left ventricular ejection fraction in five-day 
transplantation group had moved up to about 50% and the ten-day group reached almost 60%, 
doing significantly better than the control groups.  Left ventricle wall thickening also improved 
significantly in the 10-day group, as opposed to the others.  While scar formation was extremely 
noticeable in hearts injected with buffered solution, scar size was smaller in groups that received 
the HUCBC injection, more so in the five and ten day groups than the others.  When injected 
cells were immunostained with anti-human leukocyte antigen, it was observed that only cells 
delivered in the ten-day group had settled in the infarct zone in the myocardium enough to make 
a difference.   New angiogensis was due to the endothelial progenitors found in HUCBC.  
Microvasculature density was significantly greater in the five-day and ten-day groups than in 
their controls, and was altogether greater in the ten-day group.   Myocardial infarction is a time 
dependent process, based on the loss of effective cardiomyocytes and the formation of scar 
tissue.  The process begins with an inflammation of the infarct zone, and this reaction is nearly 
complete at ten days post myocardial infarction.  It can be concluded that this is the best 
environment for stem cell homing and survival (Xing, Yun-li et al. 2009).   
Tissue Engineering 
Cardiac muscle tissue has a very quick and active metabolism.  It therefore requires a lot 
of oxygen and nutrition.  In natural cardiac tissue, almost every cardiomyocyte can be found in 
close proximity to a capillary vessel, ensuring that each cell is properly perfused and taken care 
of.  Cardiac cell density is much higher than most other tissues.  In a normal heart, non-
cardiomyocyte cells such as vascular endothelial cells, smooth muscle cells, and fibroblasts make 
up 70% of the tissue.  These non-cardiac cells are integral to normal heart functioning.   All these 
factors together make it very difficult to artificially create cardiac muscle (Guo et al. 2009). 
One study investigated the effects of co-seeding rat mesenchymal stem cells with 
embryonic cardiomyocytes. The scientists conducting the study believed that the only way to 
attempt to engineer cardiac muscle is in three dimensions, so they constructed a three 
dimensional tubular scaffold called a myotubule.  They fed liquid collagen between two rotating 
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cones, resulting in a cylindrical tube of collagen fibrils with a hollow, inner central lumen.   To 
isolate the mesenchymal stem cells, they anesthetized 300 rats and removed the femoral and 
tibial bones.  The marrow cavities were flushed and the marrow was combined.  The bone 
marrow was passed through thin needles to break up clumps, and the single cell suspensions that 
resulted were centrifuged for five minutes at 200g. Cells were trypsinized three times, and 
replated. Only bone marrow stromal cells remained. Cells were labeled with green fluorescent 
protein for lineage tracing, and were replated for subculturing.   Embryonic cardiac myocytes 
were collected from rat embryos. Upon the dissection of their hearts, the atria were discarded. 
The ventricles were minced and incubated, and centrifuged, until ventricular primary cells could 
be isolated.  The embryonic ventricular cardiomyocytes (ECMs)  were planted in a medium 
filled collagen tube alone, and a combination of ECMs were seeded together with mesenchymal 
stem cells.  The results of both experiments were studied at seven, fourteen, twenty one, and 
twenty eight days.  Gene expression of the tissue in both myotubules was studied in order to 
analyze cardiogenic differentiation.  In order to validate findings of cardiac myocyte markers in 
these collagen tube cultures, cardiac specific markers were immunocytochemically stained.  This 
was done using antibodies directed against specific cardiac transcription factors, hormones, 
contractile and structural filaments, and junctional proteins.  Through staining and lasers, it was 
established that the cells located in the myotubes tested positive for many cardiomyocyte 
markers, including myosin heavy chains, sarcomeric myosin heavy chains (a contractile protein), 
cardiac troponin, cardiac actinin and desmin, GATA binding proteins, peptide hormones ANP 
and BNP, and others (Valarmathi et al. 2010). 
At 21 days, ECM tube cultures showed the presence of myocytes mainly on the luminal 
and outer surfaces of the construct. External to the tubule, ECMs aligned and overlapped in an 
orderly manner, but cells on the inner luminal surface showed cord like cellular arrangement that 
resembles that of in-vivo myocytes.  These cells showed signs of developing sarcomeric units, 
and tested positive for actin and myosin.  They indicated progressive differentiation towards in-
vivo neonatal-like ventricular cardiac muscle cells.  In MSC/ ECM co-cultures, the 
differentiating cells appeared organized into many layers of intercalated bundles and branches 
throughout the myotubule.  Cross bridges and specialized cell junctions were evident.  The 
maturing cardiomyocytes showed evidence of evolving into Z-disks and into cardiac specific 
sarcomeric arrangements, and showed promise for cardiac biosynthetic activities.  The MSCs 
that had been immunostained showed markers associated with cardiomyocytes, including myosin 
heavy chains and other aforementioned characteristic, proving that it wasn’t only the ECMs 
affecting the expression of cardiac properties. In comparison to the ECM only construct, 
hormone secretion levels of the MSCs/ECMs stayed strong and constant. The cells were 
metabolically active.  When tested under electron microscope, the nuclei of ECMs were typical 
of underdeveloped embryonic cardiac muscle cells. The MSCs/ECMs co-culture revealed the 
typical appearance of developing cardiomyocytes. Cells were elongated, multilayered, and 
orderly. Myofilaments were present, if randomly dispersed throughout.  Plus, the cells showed 
developing mitochondria and vescicles of the active cardiomyocyte. MSCs/ECMs combination 
expressed cardiac specific genes, proteins, ion channels, receptors. In addition spontaneous, 
synchronized contraction of the culture was evident through the transparent myotubule 
(Valarmathi et al. 2010). 
Previous successes in the implantation of engineered cardiac tissue have failed due to 
necrosis at the core of the transplanted tissue and poor survival related to ischemic injury.  
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Bioengineers have long sought a solution to this problem.  Human embryonic stem cells were 
differentiated into cardiomyocytes and suspended in a rotating orbital shaker, resulting in human 
cardiac tissue patches, composed of enriched cardiomyocytes.  These patches, however, did not 
survive transplantation in-vivo.  Scientists tried heat shocking the patches a day before 
implantation and bathing them in prosurvival cocktail before implanting them into skeletal 
muscle of nude rats. At one week, they found only rare, isolated human cardiac muscle cells. The 
peripheral edges of the tissue were viable, but the entire inner core was dead.  They deduced that 
the problem was in large part due to the ischemic injury at the infarct zone, and that the patches 
were too thick for nutrients to diffuse into the core, and that in order for the procedure to be 
successful, the tissue needed to be vascularized.  The tissue patches died before host 
angiogenesis could provide them with a normal blood supply (Stevens et al. 2009). 
Tri-cell cardiac patches were scientists’ next attempt.  Human embryonic stem cell 
derived cardiomyocytes were combined with human umbilical vein endothelial cells (HUVEC) 
and mouse embryonic fibroblasts in a 1:1:0.5 ratio in a medium of human embryoid bodies (a 
cluster of heterogeneous embryonic stem cells that are set to differentiate to a specific lineage 
[Itskovitz-Eldor et al. 1999]).  The newly created tissue had endothelial cell networks that 
resembled a vascular plexus.  The next logical step was to test the contractility of the new tissue.  
Patches were stimulated using square waves of frequency and contraction was monitored via 
video edge detection.  Cardio-HUVEC-MEF patches were cultured for 2-3 days before testing. 
They routinely contracted when stimulated by 2 Hz of electricity (120 beats/minute), but 
couldn’t keep pace with 5 Hz of stimulation. When stimulated at higher frequencies, the patches 
never fully relaxed, and a decrease in contractile ability resulted. Another important 
consideration for scientists to take into account are the passive mechanical properties of cardiac 
tissue, especially in relation to diastolic filling. The passive stiffness of Cardio-HUVEC-MEF 
patches were tested in comparison to cardio only patches by using strips cut from each patch. 
They were stretched in increasing length increments. At 7.9 mN/mm2, cardio-HUVEC-MEF 
constructs were closer to the stiffness of neonatal pig myocardium than cardio-only patches.  
When tested, scientists saw that the cardio-HUVEC-MEF constructs produced more connective 
tissue and collagen fibrils per area, making their stiffness more physiologically appropriate.  
These patches were a thousand times less stiff than the collagen scar that forms as a result of 
myocardial infarction, suggesting that they would impede much less on diastolic filling (Stevens 
et al 2009). 
The next step for scientists was to test whether or not these vascularized human cardiac 
tissue patches could survive implantion in vivo.  Prior to their implantation into the gluteus 
muscle of nude rats, cardio-only and cardio-HUVEC-MEF patches were heat shocked and 
bathed in pro-survival cocktail.  At one week post implantation, the rats were killed.  Human 
cardiomyocytes and endothelial cells were indentified through the immunohistochemical staining 
of β-myosin heavy chain and human complement proteins. In cardio-only patches, only the 
occasional, isolated human cardiomyocytes were detected. Comparably, cardio-HUVEC-MEF 
patches formed much larger grafts of human myocardial tissue. The cardiac muscle cells showed 
small, sarcomeric arrangements.  Many human endothelial cells could be found among the 
patches, some of them even containing traces of red blood cells.  Despite the fact that cardio-only 
patches were produced from 50% more cardiomyocytes, implanted cardio-HUVEC-MEF patches 
grew to be 11 times larger.  Next, the cardio-HUVEC-MEF constructs were sutured into the 
hearts of nude rats.  The patches had attached to the hearts of all test subjects.  The microvessels 
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that had formed contained red blood cells and white blood cells, indicated that the new vessels 
had anastomosed with the normal rat blood vessels, creating a much more ideal environment for 
tissue survival.  (Stevens et al. 2009). 
In the ten years that scientists have been experimenting with tissue engineering, much 
progress had been made.  Nevertheless, there are still many obstacles that need to be overcome 
before newly synthesized cardiac tissue can be used to alleviate the effects of myocardial 
infarction.  One of the largest problems facing bioengineers is constructing tissue the proper size 
and shape to fit into human myocardium.   So far, no three dimensional tissue construct has been 
thick enough or large enough.  Three to four cardiomyocyte monolayers have been successfully 
stacked one on top of the other, but the thickness hasn’t come close to that of human cardiac 
tissue.  As for shape, researchers have been able to construct tissue in rings, strips, and squares.  
While each of those shapes has its own advantage, none of them come close to the shape of a 
natural human heart.  Of course, another large issue is immunorejection.  None of the methods 
developed thus far have used or yielded autologus material.  All implantation studies have used 
immunosuppressants.  Another commonly overlooked problem is that most media supplements 
used to grow the tissue are xenogenic, resulting in several issues including infection.  New, non-
xenogenic growth media must be developed before engineered tissue can successfully be 
transplanted into humans (Xing, Yu-jie et al. 2009 b).  Until this tissue has been successfully 




 Because myocardial infarction and the death of cardiac muscle has always been 
seen as irreversible, researchers have been working on many different ways to reverse the 
process and regenerate cardiac muscle.   In most studies, heart function was partially, if not 
mostly restored, even if cardiac muscle itself was not actually produced.  The reperfusion of 
existing muscle and the prevention of scar formation definitely played a part in reestablishing 
cardiac function and preventing further heart complications.   Researchers discovered the 
existence of cardiac progenitor cells and have begun to experiment with them.  Tissue has been 
engineered and successfully transplanted into rats.  Much progress has been made in the field, 
though there are still obstacles that need to be overcome.  Many studies featured embryonic cells, 
the use of which is still extremely controversial, and may lead to tumor formation in the long run 
(Joggerst and Hatzopoulos 2009).  Finally, more human trials need to be done to prove the safety 
and benefits of cell therapy and tissue transplantation. 
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